Courtney Marabella

Senior Editor, OncLive®
Courtney Marabella joined the MJH Life Sciences team in 2021 and is Senior Editor for OncLive®. Prior to joining the company she worked as the Audience Development Editor for the Asbury Park Press, part of the USA Today Network. Email: cmarabella@onclive.com

Articles

HEPZATO Demonstrates Promising Preliminary Activity in Metastatic Ocular Melanoma

March 31st 2021

HEPZATO KIT has demonstrated statistically significant benefit compared to best alternative care in patients with liver-dominant metastatic ocular melanoma, according to preliminary results from the phase 3 FOCUS trial.

Novel NTD Inhibitor EPI-7386 Plus Enzalutamide Under Evaluation in mCRPC

March 31st 2021

The first-in-class N-terminal domain androgen receptor inhibitor EPI-7386 is being examined in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer as part of a phase 1/2 trial.

Noninvasive cfDNA Blood Test for Advanced Adenoma and CRC Under Exploration

March 31st 2021

A prospective, multicenter, observational USOPTIVAL study has been initiated in the United States to examine an investigational cell-free DNA blood test to detect advanced adenoma and colorectal cancer.

COVID-19 and Cancer Care: Lessons Learned 1 Year Later

March 31st 2021

From delayed diagnoses, to the emergence of telemedicine, to managing the increased emotional burden experienced by patients and healthcare professionals alike, the community has been forced to approach cancer care in ways they never had before in light of the COVID-19 pandemic.

Mirvetuximab Soravtansine/Rucaparib Shows Early Tolerability, Activity in Ovarian and Endometrial Cancers

March 29th 2021

The combination of mirvetuximab soravtansine and rucaparib was found to be well tolerated, with encouraging activity reported in heavily pretreated patients with endometrial, ovarian, fallopian tube, or primary peritoneal cancer.

Liso-Cel Approved in Japan for Relapsed/Refractory Large B-Cell Lymphoma

March 29th 2021

Japan’s Ministry of Health, Labour and Welfare has approved lisocabtagene maraleucel, a CAR T-cell therapy designed to target CD19, for the treatment of patients with relapsed or refractory large B-cell lymphoma, as well as relapsed/refractory follicular lymphoma.

Chemotherapy Plus Immunotherapy Shows No Benefit Following Osimertinib in EGFR+ NSCLC

March 26th 2021

Treatment with chemotherapy plus immunotherapy did not demonstrate significant clinical benefit over chemotherapy alone in patients with EGFR-mutated non–small cell lung cancer after progression on osimertinib.

Tipifarnib Showcases Encouraging Efficacy in Relapsed or Metastatic HRAS-Mutant HNSCC

March 26th 2021

Tipifarnib showed promising clinical activity in patients with recurrent and/or metastatic, HRAS-mutant head and neck squamous cell carcinoma whose disease had progressed after prior therapy.

FASN Inhibitor AZ12756122 Reduces Resistance Properties in EGFR TKI–Resistant, EGFR-Mutant NSCLC Models

March 25th 2021

The fatty acid synthase inhibition caused by AZ12756122 could represent a promising therapeutic alternative to overcome resistance to EGFR TKIs because of the synergistic interaction that it has with osimertinib and its ability to reduce cancer stem cell properties in EGFR-mutant non–small cell lung cancer cell models.

Northfelt Navigates Advances Made to Improve iDFS, Reduce Relapse Risk in ER+ Breast Cancer

March 24th 2021

Donald W. Northfelt, MD, MS, FACP, discusses the progress made with CDK4/6 inhibitors in the treatment of patients with ER-expressing breast cancer and pivotal trials that have moved the needle forward.

Portnoy Previews Immunotherapy Breakthroughs Shaking Up Frontline SCLC Paradigm

March 24th 2021

David C. Portnoy, MD, FACP, discusses ongoing studies examining immunotherapy and what is needed to move the needle forward in SCLC.

Messersmith Makes Sense of the Novel Approaches on the Rise in GI Malignancies

March 23rd 2021

The pipeline of new agents in gastrointestinal cancers is robust, with the emergence of several antibody-drug conjugates, KRAS G12C inhibitors, and novel TKI/immune checkpoint inhibitor combinations.

AVB-500/Paclitaxel Demonstrates Clinical Benefit in Platinum-Resistant Ovarian Cancer

March 23rd 2021

The GAS6/AXL inhibitor AVB-500, when combined with paclitaxel, elicited clinical benefit with favorable tolerability in patients with platinum-resistant ovarian cancer, according to data from a phase 1b study.

Eribulin Demonstrates Limited Activity in Advanced or Recurrent Cervical Cancer

March 20th 2021

Eribulin induced limited activity with a favorable toxicity profile in patients with recurrent or advanced cervical cancer, and prior exposure to paclitaxel was associated with decreased response to the agent.

Liso-Cel Shows Encouraging Clinical Activity, Safety in Relapsed/Refractory MCL

March 19th 2021

M Lia Palomba, MD, discusses the data from the TRANSCEND-NHL-001 trial and projected how lisocabtagene maraleucel could fit into the treatment paradigm for patients with MCL.

HCC-TAG Conference to Highlight Headway Made in HCC Care Amidst COVID-19 Pandemic

March 19th 2021

Anjana Pillai, MD, discusses recent advances made in the HCC treatment paradigm, as well as what the conference will offer to healthcare providers working in the field.

Santos Spotlights Success With Checkpoint Inhibition in Frontline Metastatic NSCLC

March 18th 2021

Edgardo Santos, MD, FACP, discusses advances made with immunotherapy regimens in the first-line treatment of patients with metastatic non–small cell lung cancer and areas of active investigation.

Promises and Pitfalls of MRD as a Potential Surrogate End Point in AML

March 18th 2021

Jerald Radich, MD, highlights the role minimal residual disease in acute myeloid leukemia, how different technological advanced have increased the application of MRD-based strategies, and ongoing efforts that are being made to address remaining questions.

Cilta-Cel Demonstrates Durable Responses in Relapsed/Refractory Multiple Myeloma

March 17th 2021

Ciltacabtagene autoleucel has a manageable safety profile at its recommended phase 2 dose, and yielded early, deep, and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

Risk-Adapted CAR T Dosing Maintains Efficacy, Improves Safety in Pediatric Relapsed/Refractory ALL

March 15th 2021

A risk-adapted CD19 CAR T-cell therapy dosing approach allowed pediatric patients with relapsed/refractory acute lymphocytic leukemia to maintain a high rate of remission, while reducing the risk of severe toxicities among those with a high initial disease burden